Page 1111 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 61 Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome in Adults 980.e1

REFERENCES 20. Middeke JM, Beelen D, Stadler M, et al: Outcome of high-risk acute
myeloid leukemia after allogeneic hematopoietic cell transplantation:
1. Alyea EP, Kim HT, Ho V, et al: Impact of conditioning regimen inten- negative impact of abnl(17p) and -5/5q. Blood 120:2521, 2012.
sity on outcome of allogeneic hematopoietic cell transplantation for 21. Mohr B, Schetelig J, Schafer-Eckart K, et al: Impact of allogeneic
advanced acute myelogenous leukemia and myelodysplastic syndrome. haematopoietic stem cell transplantation in patients with abnl(17p)
Biol Blood Marrow Transplant 12:1047, 2006. acute myeloid leukaemia. Br J Haematol 161:237, 2013.
2. Gupta V, Tallman MS, Weisdorf DJ: Allogeneic hematopoietic cell 22. Middeke JM, Fang M, Cornelissen JJ, et al: Outcome of patients with
transplantation for adults with acute myeloid leukemia: myths, con- abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem
troversies, and unknowns. Blood 117:2307, 2011. cell transplantation. Blood 123:2960, 2014.
3. Brunstein CG, Fuchs EJ, Carter SL, et al: Alternative donor transplan- 23. Mohty M, de Lavallade H, Ladaique P, et al: The role of reduced inten-
tation: results of parallel phase 2 trials using HLA-mismatched related sity conditioning allogeneic stem cell transplantation in patients with
bone marrow or unrelated umbilical cord blood grafts. Blood 118:282, acute myeloid leukemia: a donor vs no donor comparison. Leukemia
2011. 19:916, 2005.
4. Passweg JR, Baldomero H, Bader P, et al: Hematopoietic SCT in 24. Luger SM, Ringden O, Zhang MJ, et al: Similar outcomes using
Europe 2013: recent trends in the use of alternative donors showing myeloablative vs reduced-intensity allogeneic transplant preparative
more haploidentical donors but fewer cord blood transplants. Bone regimens for AML or MDS. Bone Marrow Transplant 47:203, 2011.
Marrow Transplant 50:476, 2015. 25. Bornhauser M, Kienast J, Trenschel R, et al: Reduced-intensity con-
5. Armand P, Kim HT, Cutler CS, et al: Prognostic impact of elevated ditioning versus standard conditioning before allogeneic haemopoietic
pretransplantation serum ferritin in patients undergoing myeloablative cell transplantation in patients with acute myeloid leukaemia in first
stem cell transplantation. Blood 109:4586, 2007. complete remission: a prospective, open-label randomised phase 3 trial.
6. Burnett A, Wetzler M, Lowenberg B: Therapeutic advances in acute Lancet Oncol 13:1035, 2012.
myeloid leukemia. J Clin Oncol 29:487, 2011. 26. Gupta V, Tallman MS, He W, et al: Comparable survival after HLA-
7. Koreth J, Schlenk R, Kopecky KJ, et al: Allogeneic stem cell trans- well-matched unrelated or matched sibling donor transplantation for
plantation for acute myeloid leukemia in first complete remission: acute myeloid leukemia in first remission with unfavorable cytogenetics
systematic review and meta-analysis of prospective clinical trials. JAMA at diagnosis. Blood 116:1839, 2010.
301:2349, 2009. 27. Basara N, Schulze A, Wedding U, et al: Early related or unrelated
8. Paschka P, Marcucci G, Ruppert AS, et al: Adverse prognostic signifi- haematopoietic cell transplantation results in higher overall survival and
cance of KIT mutations in adult acute myeloid leukemia with inv(16) leukaemia-free survival compared with conventional chemotherapy in
and t(8;21): a Cancer and Leukemia Group B study. J Clin Oncol high-risk acute myeloid leukaemia patients in first complete remission.
24:3904, 2006. Leukemia 23:635, 2009.
9. Schnittger S, Kohl TM, Haferlach T, et al: KIT-D 816 mutations in 28. Schlenk RF, Dohner K, Mack S, et al: Prospective evaluation of allo-
AML1-ETO-positive AML are associated with impaired event-free and geneic hematopoietic stem-cell transplantation from matched related
overall survival. Blood 107:1791, 2006. and matched unrelated donors in younger adults with high-risk acute
10. Dohner H, Estey EH, Amadori S, et al: Diagnosis and management myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol
of acute myeloid leukemia in adults: recommendations from an inter- 28:4642, 2010.
national expert panel, on behalf of the European Leukemianet. Blood 29. Walter RB, Pagel JM, Gooley TA, et al: Comparison of matched
115:453, 2010. unrelated and matched related donor myeloablative hematopoietic
11. Schlenk RF, Dohner K, Krauter J, et al: Mutations and treatment cell transplantation for adults with acute myeloid leukemia in first
outcome in cytogenetically normal acute myeloid leukemia. N Engl J remission. Leukemia 24:1276, 2010.
Med 358:1909, 2008. 30. Laughlin MJ, Eapen M, Rubinstein P, et al: Outcomes after transplan-
12. Marcucci G, Radmacher MD, Maharry K, et al: MicroRNA expres- tation of cord blood or bone marrow from unrelated donors in adults
sion in cytogenetically normal acute myeloid leukemia. N Engl J Med with leukemia. N Engl J Med 351:2265, 2004.
358:1919, 2008. 31. Rocha V, Labopin M, Sanz G, et al: Transplants of umbilical-cord blood
13. Renneville A, Boissel N, Gachard N, et al: The favorable impact of or bone marrow from unrelated donors in adults with acute leukemia.
CEBPA mutations in patients with acute myeloid leukemia is only N Engl J Med 351:2276, 2004.
observed in the absence of associated cytogenetic abnormalities and 32. Eapen M, Rocha V, Sanz G, et al: Effect of graft source on unrelated
FLT3 internal duplication. Blood 113:5090, 2009. donor haemopoietic stem-cell transplantation in adults with acute
14. Dufour A, Schneider F, Metzeler KH, et al: Acute myeloid leukemia leukaemia: a retrospective analysis. Lancet Oncol 11:653, 2010.
with biallelic CEBPA gene mutations and normal karyotype represents 33. Atsuta Y, Suzuki R, Nagamura-Inoue T, et al: Disease-specific analyses
a distinct genetic entity associated with a favorable clinical outcome. J of unrelated cord blood transplantation compared with unrelated bone
Clin Oncol 28:570, 2010. marrow transplantation in adult patients with acute leukemia. Blood
15. Becker H, Marcucci G, Maharry K, et al: Favorable prognostic impact 113:1631, 2009.
of NPM1 mutations in older patients with cytogenetically normal 34. Brunstein CG, Gutman JA, Weisdorf DJ, et al: Allogeneic hematopoi-
de novo acute myeloid leukemia and associated gene- and microrna- etic cell transplantation for hematologic malignancy: relative risks and
expression signatures: a Cancer and Leukemia Group B Study. J Clin benefits of double umbilical cord blood. Blood 116:4693, 2010.
Oncol 28:596, 2010. 35. Rio B, Chevret S, Vigouroux S, et al: Decreased nonrelapse mortality
16. Rockova V, Abbas S, Wouters BJ, et al: Risk stratification of after unrelated cord blood transplantation for acute myeloid leukemia
intermediate-risk acute myeloid leukemia: integrative analysis of a mul- using reduced-intensity conditioning: a prospective phase II multicenter
titude of gene mutation and gene expression markers. Blood 118:1069, trial. Biol Blood Marrow Transplant 21:445, 2015.
2011. 36. Wang HX, Yan HM, Wang ZD, et al: Haploidentical hematopoietic
17. Breems DA, Van Putten WL, De Greef GE, et al: Monosomal karyo- stem cell transplantation in hematologic malignancies with G-CSF
type in acute myeloid leukemia: a better indicator of poor prognosis mobilized bone marrow plus peripheral blood stem cells grafts without
than a complex karyotype. J Clin Oncol 26:4791, 2008. t cell depletion: a single center report of 29 cases. Leuk Lymphoma
18. Breems DA, Lowenberg B: Acute myeloid leukemia with monosomal 53:654, 2011.
karyotype at the far end of the unfavorable prognostic spectrum. 37. Huang XJ, Chang YJ: Unmanipulated HLA-mismatched/haploidenti-
Haematologica 96:491, 2011. cal blood and marrow hematopoietic stem cell transplantation. Biol
19. Oran B, Dolan M, Cao Q, et al: Monosomal karyotype provides Blood Marrow Transplant 17:197, 2011.
better prognostic prediction after allogeneic stem cell transplantation 38. Aversa F: Haploidentical haematopoietic stem cell transplantation for
in patients with acute myelogenous leukemia. Biol Blood Marrow acute leukaemia in adults: experience in Europe and the United States.
Transplant 17:356, 2011. Bone Marrow Transplant 41:473, 2008.